Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacological Countermeasures for High Altitude Readiness
NCT05300477Phase 4Active, not recruiting
- Sponsor
- U.S. Army Research Institute of Environmental Medicine
- Start
- May 2022
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of erythropoietin in acute mountain sickness (AMS) (2 arms), sponsored by U.S. Army Research Institute of Environmental Medicine. Primary endpoint: 3.2 km self-paced treadmill time trial performance at 35 minutes. Started May 2022; status: active, not recruiting.
02
Drugs
erythropoietin
03
Conditions
acute mountain sickness (AMS)
Beyond the preview
Go deeper on NCT05300477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05300477.